03.04.15
Franklin Lakes, N.J.-based Becton, Dickinson and Co. (BD) has purchased CRISI Medical Systems, a San Diego, Calif.-based medical technology company that makes drug-delivery systems.
Financial details on the acquisition were not disclosed.
The acquisition furthers, according to BD officials, adds to their firm’s portfolio of products that address preventable medication errors and improve care delivery efficiencies.
BD and CRISI entered into an exclusive partnership in June 2013 to jointly develop the BD Intelliport Medication Management System, a first-of-its-kind medication management solution for manual intravenous (IV) bolus injections. According to information From BD, he Intelliport system provides real-time drug identification, dose measurement and allergy detection at the point of injection while wirelessly sending captured information directly into the patient's electronic medical record following medication administration.
The Intelliport system received clearance from the U.S. Food and Drug Administration in December 2014 and is expected to be commercially available in spring 2015.
"We are very excited about the CRISI acquisition. It gives BD access to the injection safety market with a differentiated platform that we believe, when combined with our pending
CareFusion acquisition, will significantly enhance our growing end-to-end IV medication safety offering," said Tom Polen, segment president, BD Medical. "The Intelliport system fills a need that has remained unmet for decades—the use of technology to reduce the likelihood of human error in the practice of injectable medication delivery."
BD is in the process of one of the medtech industry’s largest recent acquisitions. The company is busying CareFusion for $12.2 billion. The deal was announced in October.
"We found the perfect partner in BD and are very pleased to have been on this journey together to create and introduce the Intelliport system to the medical community," said Michael K. Perry, CEO of CRISI Medical Systems.
"By combining forces with CRISI, BD will continue moving forward with raising awareness of preventable medication errors. We will also have a sophisticated offering to help support healthcare providers in their efforts to exceed compliance standards while delivering safe and exceptional patient care," said William A. Tozzi, president, BD Medical,
Medical Surgical Systems. "We are pleased to welcome this new platform to BD."
BD’s technology is focused on improving drug delivery, enhancing the diagnosis of infectious diseases and cancers, supporting the management of diabetes and advancing cellular research.
Financial details on the acquisition were not disclosed.
The acquisition furthers, according to BD officials, adds to their firm’s portfolio of products that address preventable medication errors and improve care delivery efficiencies.
BD and CRISI entered into an exclusive partnership in June 2013 to jointly develop the BD Intelliport Medication Management System, a first-of-its-kind medication management solution for manual intravenous (IV) bolus injections. According to information From BD, he Intelliport system provides real-time drug identification, dose measurement and allergy detection at the point of injection while wirelessly sending captured information directly into the patient's electronic medical record following medication administration.
The Intelliport system received clearance from the U.S. Food and Drug Administration in December 2014 and is expected to be commercially available in spring 2015.
"We are very excited about the CRISI acquisition. It gives BD access to the injection safety market with a differentiated platform that we believe, when combined with our pending
CareFusion acquisition, will significantly enhance our growing end-to-end IV medication safety offering," said Tom Polen, segment president, BD Medical. "The Intelliport system fills a need that has remained unmet for decades—the use of technology to reduce the likelihood of human error in the practice of injectable medication delivery."
BD is in the process of one of the medtech industry’s largest recent acquisitions. The company is busying CareFusion for $12.2 billion. The deal was announced in October.
"We found the perfect partner in BD and are very pleased to have been on this journey together to create and introduce the Intelliport system to the medical community," said Michael K. Perry, CEO of CRISI Medical Systems.
"By combining forces with CRISI, BD will continue moving forward with raising awareness of preventable medication errors. We will also have a sophisticated offering to help support healthcare providers in their efforts to exceed compliance standards while delivering safe and exceptional patient care," said William A. Tozzi, president, BD Medical,
Medical Surgical Systems. "We are pleased to welcome this new platform to BD."
BD’s technology is focused on improving drug delivery, enhancing the diagnosis of infectious diseases and cancers, supporting the management of diabetes and advancing cellular research.